PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Short Interest Update

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 17,200 shares, a growth of 152.9% from the August 31st total of 6,800 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily volume of 16,800 shares, the short-interest ratio is presently 1.0 days.

PharmaCyte Biotech Stock Performance

Shares of NASDAQ:PMCB opened at $1.84 on Friday. The stock has a 50-day simple moving average of $1.80 and a 200-day simple moving average of $2.03. The stock has a market capitalization of $15.55 million, a P/E ratio of -1.53 and a beta of -0.22. PharmaCyte Biotech has a 1 year low of $1.39 and a 1 year high of $2.58.

PharmaCyte Biotech (NASDAQ:PMCB) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.85) earnings per share (EPS) for the quarter.

Institutional Trading of PharmaCyte Biotech

An institutional investor recently raised its position in PharmaCyte Biotech stock. K2 Principal Fund L.P. lifted its stake in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) by 17.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 304,613 shares of the company’s stock after buying an additional 46,132 shares during the period. K2 Principal Fund L.P. owned approximately 3.53% of PharmaCyte Biotech worth $655,000 as of its most recent SEC filing. Institutional investors and hedge funds own 34.24% of the company’s stock.

PharmaCyte Biotech Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.